AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Anteo Diagnostics Limited (ASX:ADO) is a nanotechnology company. It is into development and commercializing of products in the life sciences research, diagnostics, energy and in the market for medical devices. Anteo Technologies Pty Ltd is a fully-owned subsidiary of Anteo Diagnostics Ltd.
On 17 January 2018, the company has announced a new collaboration signed with Canadian Stock Exchange-listed Sona Nanotech Inc. Both the parties will combine their respective technologies to co-develop new products that have the potential to speed up the development and improve the performance of lateral flow immunoassays.Â
Lateral flow tests are used to detect if any target is present in a liquid sample without resorting to specialized and costly equipment, which is also known as lateral flow immunoassays. These tests are generally used for medical diagnostics either for home testing, point of care testing, or laboratory clinic use.
AnteoBind is becoming reputed and playing an important, performance-enhancing role in the development of lateral flow tests. However, with this collaboration, Anteo and Sona will use important POC targets in the fields of Cardiac, Sepsis and Pregnancy testing to assess the improvements that can be achieved to these lateral flow tests. If the company can generate any positive results, it will encourage the global developers of lateral flow tests in these, and other important testing areas, to adopt Anteo and Sonaâs new, co-developed products.
Sona has lodged the attached press release on the Canadian Stock Exchange which provides a comprehensive overview of the collaboration.
The Chief Executive Officer of Anteo, Christopher Parker was pleased to announce about the progress and building of the companyâs pipeline for commercial collaborations. Sona is an example of the growing appeal and broad adaptability of AnteoBind for Life Sciences, Diagnostics, and Point of Care device companies. As mentioned, the company will report on the progress of this new collaboration going forward.
The CEO of Sona Darren Rowles said that the project has an objective of developing sets of reagents together, that can benefit all lateral flow assay developers worldwide, by providing products that can reduce the time for the key production process and will increase the performance of tests.
As agreed, Sona Nanotech will supply its unique, gold nanorod technology to Anteo. This technology will be combined with the proprietary AnteoBind technology. Anteo will help Sona Nanotech in conducting its in-house assessment and to assess the lateral flow assay format.
As far as the performance of Anteo Diagnosticâs stock and return is concerned which has posted over the last few months. Currently, it is trading at a price of $0.018 with the market capitalization of ~$20.88 million. The stock opened at $0.020 with a day high of $0.021 and a day low of $0.018. The company posted returns of 38.46% and 5.88% over the last three months and one-month period respectively. It has a 52-week high price of $0.024 and a 52-week low of $0.010, with an average volume of ~4.23 million approximately.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
